Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis

BACKGROUND: B cells are critical mediators of systemic lupus erythematosus (SLE) and lupus nephritis (LN), and antinuclear antibodies can be found in the serum of approximately 98% of patients with SLE. Spleen tyrosine kinase (SYK) is a nonreceptor tyrosine kinase that mediates signaling from immuno...

Descripción completa

Detalles Bibliográficos
Autores principales: Pohlmeyer, Christopher W., Shang, Ching, Han, Pei, Cui, Zhi-Hua, Jones, Randall M., Clarke, Astrid S., Murray, Bernard P., Lopez, David A., Newstrom, David W., Inzunza, M. David, Matzkies, Franziska G., Currie, Kevin S., Di Paolo, Julie A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008554/
https://www.ncbi.nlm.nih.gov/pubmed/33781343
http://dx.doi.org/10.1186/s41927-021-00178-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008554/
https://www.ncbi.nlm.nih.gov/pubmed/33781343
http://dx.doi.org/10.1186/s41927-021-00178-3

Ejemplares similares